Search for: "Commitment of J F" Results 1601 - 1620 of 1,900
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Feb 2010, 6:55 am by Jacob Katz Cogan
The region’s commitment to what some call the “Asian way” has sometimes privileged consultation and consensus over clear and binding obligations. [read post]
14 Feb 2010, 12:13 pm
A review of our records also revealed that your firm has not listed its product as required by section 510(j) of the Act. [read post]
14 Feb 2010, 12:13 pm
A review of our records also revealed that your firm has not listed its product as required by section 510(j) of the Act. [read post]
12 Feb 2010, 6:56 am by Sean Patrick Donlan
F von Benda-Beckmann, K von Benda-Beckmann, and J Eckert (eds), Rules of law and laws of ruling: on the govenance of law (2009)Offering an anthropological perspective, this volume explores the changing relations between law and governance, examining how changes in the structure of governance affect the relative social significance of law within situations of legal pluralism. [read post]
5 Feb 2010, 4:24 am by Andrew Frisch
J & J trained its representatives to gauge a doctor’s interest and knowledge about the product, eventually building to a “commitment” to prescribe the drug. [read post]
1 Feb 2010, 9:57 am by Steve Hall
Jackels, Catholic Diocese of Wichita; Scott J. [read post]
Editor’s Note: Eduardo Gallardo is a partner focusing on mergers and acquisitions at Gibson, Dunn & Crutcher LLP. [read post]
24 Jan 2010, 11:15 am by Ray Dowd
    The question of whether Article 5 and Section 412 conflict were not reached, leaving the question in the hands of diplomats.Copyright Litigation Handbook (West 4th Ed. 2009) by Raymond J. [read post]
24 Jan 2010, 9:40 am
Your promotion and introduction into interstate commerce of the BioFind III (or Biofind), BioPack II (or BioPack), Light Patch, Spinal Pad, and the Knee Saver for these uncleared indications render them adulterated under section 501 (f)(1)(B) of the Act, for failure to obtain FDA premarket approval, and misbranded under section 502(o) of the Act, for failure to notify the agency of your intent to introduce the device into commercial distribution, as required by section… [read post]
24 Jan 2010, 9:40 am
Your promotion and introduction into interstate commerce of the BioFind III (or Biofind), BioPack II (or BioPack), Light Patch, Spinal Pad, and the Knee Saver for these uncleared indications render them adulterated under section 501 (f)(1)(B) of the Act, for failure to obtain FDA premarket approval, and misbranded under section 502(o) of the Act, for failure to notify the agency of your intent to introduce the device into commercial distribution, as required by section… [read post]
23 Jan 2010, 6:53 pm by admin
The following is a summary review of articles from all over the nation concerning environmental law settlements, decisions, regulatory actions and lawsuits filed during the past week. [read post]